Atlas Trials

Pathway Mutant Myelodysplastic Syndromes

1 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Pathway Mutant Myelodysplastic Syndromes

RecordFirmDate
Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms (NCT06284460)M.D. Anderson Cancer Center2025-01-31

Track Pathway Mutant Myelodysplastic Syndromes automatically

Every clearance here is in the API, with alerts when new ones post.